RevMed Q1 net loss $453.8M, daraxonrasib shows OS 13.2 mo in pancreatic cancer

Revolution Medicines, Inc.

2026-Q1 EPS reported -$2.29

Daraxonrasib Phase 3 RASolute 302: median OS 13.2 mo vs 6.7 mo chemo (HR 0.40); NDA submission planned.
Q1 2026 net loss $453.8M vs $213.4M YoY; R&D $344M, G&A $101.3M, including $44.6M incremental SBC.
Cash $1.9B at Mar 31, 2026; April 2026 financings raised $2.225B gross from stock and convertible notes.
FY 2026 GAAP operating expense guidance raised to $1.7-1.8B due to ~$80M increase in non-cash SBC.
Appointed Neil MacGregor JPAC GM, Tetsuo Endo Japan GM, Martin Voelkl Germany GM; EAP for daraxonrasib begun.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Revolution Medicines, Inc. reported financial results for the quarter ended March 31, 2026.

Period: the quarter ended March 31, 2026
Result: reported results

Exact text from the filing

Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced its financial results for the quarter ended March 31, 2026, and provided an update on corporate progress.

View on SEC.gov

59 earnings releases filed in the last 30 days. Browse all earnings releases →

Revolution Medicines, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-208918

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.